FDA should schedule regs for revision "semi-annually" -- PhRMA comments on "ReGo".
This article was originally published in The Tan Sheet
Executive Summary
FDA REG "SEMI-ANNUAL" REVIEW RECOMMENDED BY PhRMA in Aug. 30 comments on the advanced notice of proposed rulemaking in the June 4 Federal Register covering the agency's "Reinventing Government" initiatives. The Pharmaceutical Research & Manufacturers of America urged FDA to "develop, adopt and publish a plan for periodic review of all portions of its regulations." As an example, PhRMA suggested that the agency "publish semi-annually a list of sections of the [Code of Federal Regulations] scheduled to be reviewed and revised within the next six months and in the subsequent six-month period."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning